Join
Live feed
·
PRReleasevia Quantisnow
Elicio Therapeutics Inc. logo

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

ByQuantisnow·Wall Street's wire, on your screen.
ELTX· Elicio Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELTX (Elicio Therapeutics Inc.) and more on Quantisnow.